| P50 | author | Arti Hurria | Q88804859 |
| P2093 | author name string | Robert A Figlin | |
| | Sumanta K Pal | |
| | Ari Vanderwalde | |
| P2860 | cites work | Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor | Q27824804 |
| | Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab | Q28219257 |
| | Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma | Q28247085 |
| | Sunitinib versus interferon alfa in metastatic renal-cell carcinoma | Q28282757 |
| | Sorafenib in advanced clear-cell renal-cell carcinoma | Q28282767 |
| | Population pharmacokinetics and pharmacodynamics of oral etoposide | Q28365888 |
| | Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial | Q29615711 |
| | Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial | Q29618031 |
| | Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma | Q29618608 |
| | Breaking through a Plateau in Renal Cell Carcinoma Therapeutics: Development and Incorporation of Biomarkers | Q30472042 |
| | Bayesian estimate of vinorelbine pharmacokinetic parameters in elderly patients with advanced metastatic cancer | Q33333307 |
| | Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study | Q33510317 |
| | Renal cell carcinoma therapy in 2010: many options with little comparative data. | Q33558406 |
| | Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin | Q33718099 |
| | Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206 | Q33813718 |
| | Aging and cancer in America. Demographic and epidemiologic perspectives | Q33841117 |
| | The comprehensive geriatric assessment: when, where, how. | Q33861566 |
| | Treatment Options in Metastatic Renal Cell Carcinoma: Focus on mTOR Inhibitors | Q33985467 |
| | Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival | Q34021957 |
| | Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial | Q34586436 |
| | Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy | Q34723863 |
| | Adverse effects of anticancer agents that target the VEGF pathway | Q34990961 |
| | Sporadic renal cell carcinoma in young adults: presentation, treatment, and outcome | Q34995356 |
| | Renal cell carcinoma in young adults: incidence, disease outcome and review of the literature. | Q35010605 |
| | The effect of age and gender on bladder cancer: a critical review of the literature | Q35043055 |
| | Polypharmacy in older adults with cancer | Q35584088 |
| | Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies | Q35584182 |
| | Prognostic importance of comorbidity in a hospital-based cancer registry | Q35783153 |
| | The impact of age and comorbidity on survival outcomes and treatment patterns in prostate cancer | Q36034209 |
| | Comparison of presentation and outcome for patients 18 to 40 and 60 to 70 years old with solid renal masses | Q36119632 |
| | Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). | Q36220834 |
| | Physiologic aspects of aging: impact on cancer management and decision making, part I. | Q36360612 |
| | Pharmacokinetics and toxicity of weekly docetaxel in older patients | Q36633774 |
| | Comprehensive geriatric assessment for older patients with cancer | Q36815525 |
| | International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients--an analysis of the medical literature. | Q36815528 |
| | The National Cancer Data Base report on race, age, and region variations in prostate cancer treatment | Q36884863 |
| | Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial | Q36936936 |
| | Renal cell carcinoma in young and old patients--is there a difference? | Q37040648 |
| | Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis | Q37067792 |
| | Renal cell carcinomas in children and young adults: increased incidence of papillary architecture and unique subtypes | Q77993432 |
| | Pharmacological analysis of etoposide in elderly patients with lung cancer | Q78074726 |
| | Morphologic and molecular characterization of renal cell carcinoma in children and young adults | Q80464963 |
| | Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients | Q80665192 |
| | Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy | Q80809590 |
| | Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration | Q81002008 |
| | Age and comorbidity impact surgical therapy in older bladder carcinoma patients: a population-based study | Q81134295 |
| | Renal neoplasms in younger adults: analysis of 112 tumors from a single institution according to the new 2004 World Health Organization classification and 2002 American Joint Committee on Cancer Staging System | Q81583506 |
| | Age, comorbidity, treatment decision and prognosis in lung cancer | Q82586215 |
| | Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762) | Q82985575 |
| | Evaluation of adverse events experienced by older patients participating in studies of molecularly targeted agents alone or in combination | Q83143248 |
| | Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy | Q83357792 |
| | Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206 | Q37117085 |
| | Role of age and health in treatment recommendations for older adults with breast cancer: the perspective of oncologists and primary care providers | Q37117094 |
| | Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis | Q37254387 |
| | Overcoming challenges associated with chemotherapy treatment in the senior adult population | Q37254665 |
| | The medical treatment of metastatic renal cell cancer in the elderly: position paper of a SIOG Taskforce | Q37261810 |
| | mTOR pathway and mTOR inhibitors as agents for cancer therapy | Q37347092 |
| | Polypharmacy in hospitalized older adult cancer patients: experience from a prospective, observational study of an oncology-acute care for elders unit | Q37555330 |
| | Thrombotic events in patients with cancer receiving antiangiogenesis agents | Q37585948 |
| | How to treat elderly patients with multiple myeloma: combination of therapy or sequencing. | Q37653286 |
| | Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis | Q37698956 |
| | Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials | Q37721064 |
| | Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors | Q37765246 |
| | Altered pharmacokinetics in the elderly. | Q37919206 |
| | Are older French patients as willing as older American patients to undertake chemotherapy? | Q39392345 |
| | "Real-life" results of front-line treatment with Imatinib in older patients (≥ 65 years) with newly diagnosed chronic myelogenous leukemia | Q39847714 |
| | Pharmacology of cancer chemotherapy in the older person. | Q41313391 |
| | Aging and pharmacology | Q41605760 |
| | Safety and Efficacy of Sorafenib in Elderly Patients Treated in the North American Advanced Renal Cell Carcinoma Sorafenib Expanded Access Program | Q42928398 |
| | Polypharmacy in older oncology patients and the need for an interdisciplinary approach to side-effect management | Q43549378 |
| | Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia | Q43899710 |
| | EORTC elderly task force position paper: approach to the older cancer patient | Q44084117 |
| | Adjuvant chemotherapy for stage III colon cancer: do physicians agree about the importance of patient age and comorbidity? | Q44229372 |
| | Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study | Q45069647 |
| | A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy. | Q45948421 |
| | Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. | Q46006772 |
| | Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma | Q46329140 |
| | Retrospective study of efficacy and toxicity on patients older than 70 years within a randomized clinical trial of two cisplatin-based combinations in patients with small-cell lung cancer | Q46538891 |
| | Age does not impair the efficacy of immunochemotherapy in patients with metastatic renal carcinoma | Q46663573 |
| | Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the eld | Q46726889 |
| | Factors affecting cytochrome P-450 3A activity in cancer patients. | Q47873497 |
| | Older age predicts a decline in adjuvant chemotherapy recommendations for patients with breast carcinoma: evidence from a tertiary care cohort of chemotherapy-eligible patients | Q47954792 |
| | Geriatric assessment and comorbidity. | Q50480158 |
| | Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study. | Q51927016 |
| | Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. | Q53517685 |
| | Validation of a multidimensional evaluation scale for use in elderly cancer patients | Q59504113 |
| | Developing a cancer-specific geriatric assessment | Q59566082 |
| | Senior adult oncology clinical practice guidelines in oncology | Q60152840 |
| | Pharmacokinetics and tolerance of vinorelbine in elderly patients with metastatic breast cancer | Q60685458 |
| | Renal cell carcinoma in young andold patients Comparison of prognostic pathologic variables (cell type, tumor grade and stage, and DNA ploidy pattern) and their impact on disease outcome | Q67937489 |
| | Comprehensive geriatric assessment: a meta-analysis of controlled trials | Q72235307 |
| | Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions | Q73198585 |
| | Polypharmacy in the Older Patient With Cancer | Q73671848 |
| | A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer | Q77372791 |
| | Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters | Q77841215 |
| P433 | issue | 8 | |
| P921 | main subject | renal cell carcinoma | Q1164529 |
| | metastatic renal cell carcinoma | Q19000948 |
| P304 | page(s) | 635-649 | |
| P577 | publication date | 2011-08-01 | |
| P1433 | published in | Drugs & Aging | Q5308946 |
| P1476 | title | Systemic therapies for metastatic renal cell carcinoma in older adults | |
| P478 | volume | 28 | |